In Conversation With… Professor Paul Brogan, MBBS MRCP
"Kids aren't small adults. You have to score growth, puberty, and neurodevelopment, and weigh a symptom's impact differently in a two-year-old versus a fourteen-year-old." When Professor Paul Brogan ...
In Conversation With… Marc Judson, MD
“If the issue were just to treat sarcoidosis, I would put everyone on 40 milligrams of prednisone, and every granuloma would be destroyed. But I'm not treating sarcoidosis disease. I'm treating the ...
In Conversation With… Naomi Patel, MD MPH
“In just six months, more than 10% of patients on even moderate steroid regimens can develop new-onset diabetes.” Naomi Patel, MD MPH, a rheumatologist at Massachusetts General Hospital, is at the ...
In Conversation With… Kathy Perez
“When patients can track their own experience of steroid‑toxicity and take that data straight into the clinic, they stop being passive recipients and start driving the conversation.” Clinicians know ...
In Conversation With… Albert Whangbo, PhD
“Steroids are cheap and effective in the short term. Convincing payers that steroid-sparing therapies are worth the upfront cost is still a practical challenge.” Albert Whangbo, PhD, leads the global ...
Curious about the true cost of steroid-toxicity?
Download our infographic today
